US · Healthcare · Biotechnology
EPS came in at 0.05 against a street estimate of 0.41 — a miss of 87.8%.
Analysts rate TG Therapeutics Inc a strong buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $69.71.
CONFIDENT TG Therapeutics delivered record Q2 BRIUMVI revenue of $228M (+64% YoY), raising FY26 guidance to $890–905M US ($950M global). Phase III ENHANCE data supports single-dose IV initiation; subcutaneous Phase III readout expected by year-end with potential to double addressable market. Q2 2026 US drives growth; ex-US partner royalties and milestones accelerating. Global revenue $240M total Q2. Analysts pressed competitive dynamics vs. Roche/OCREVUS (TG gaining despite pressure), subcu Part D pricing/uptake (market research ongoing, field enthusiasm strong), and schizophrenia trial design (Fleming two-stage using biomarkers to identify responder subsets). Management conveyed confidence in all three areas but deferred specific 2027 guidance. 2026-08-03…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.41% |
| Vanguard Portfolio Management, LLC | 5.20% |
| State Street Corp | 5.09% |
| Vanguard Capital Management, LLC | 4.02% |
| Geode Capital Management, LLC | 2.38% |
| D. E. Shaw & Co LP | 2.22% |
| Soleus Capital Management, L.P. | 1.91% |
| T. Rowe Price Associates, Inc. | 1.81% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 TG THERAPEUTICS, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Product Revenue (6 months 2026): $437.1 million vs. $258.5 million in 2025 — up | 2026-08-05 |
| Results announced · Q3 2026 TG THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total global revenue: $240.3 million (up from $141.1 million in Q2 2025 | 2026-08-03 |
| Shareholder vote results · Q2 2026 SUMMARY FOR RETAIL INVESTOR HEADLINE NUMBERS • Annual meeting held June 11, 2026 with 113,003,414 shares present (73.81% of 153,093,879 outstanding | 2026-06-12 |
| Company announcement · Q2 2026 TGTX FORM 8-K SUMMARY (JUNE 3, 2026) BUSINESS & SEGMENT HIGHLIGHTS • Company announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, | 2026-06-03 |
| Company announcement · Q2 2026 SUMMARY: TG THERAPEUTICS, INC. (FORM 8-K, MAY 27, 2026) BUSINESS & SEGMENT HIGHLIGHTS • Company announced positive topline results from Phase 3 ENHA | 2026-05-27 |
| Quarterly report · Q1 2026 TG THERAPEUTICS, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Product Revenue (Q1 2026): $201.3 million vs. $119.7 million (Q1 2025) — 68% in | 2026-05-06 |
| Proxy statement · Q2 2026 TG THERAPEUTICS, INC. – PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Item 1: Elect six directors for a one-year term. Nominees are Mich | 2026-04-30 |
| Annual report FY2025 TG THERAPEUTICS, INC. - RETAIL INVESTOR SUMMARY HEADLINE NUMBERS • Public Market Valuation: ~$2.5 billion as of June 30, 2024 (market cap of non-aff | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raises full year 2026 revenue guidance to approximately $950 million TG Therapeutics reported strong Q2 2026 results with BRIUMVI (their main drug) generating $228 million in U.S. revenue, up 64% year-over-year. Total global revenue reached $240 million. The | 2026-08-03 |
| Raises full year 2026 revenue guidance to $925 million TG Therapeutics reported strong Q1 2026 results with BRIUMVI (their multiple sclerosis drug) generating $195 million in U.S. revenue, up 63% year-over-year. The company significantly raised | 2026-05-06 |
| Raises 2026 revenue guidance to $875-900 million; reports strong 2025 results TG Therapeutics reported strong 2025 financial results and raised guidance for 2026. The company's lead product BRIUMVI generated $594.1 million in U.S. revenue for 2025 (92% year-over-year | 2026-02-26 |
| Preliminary 2025 revenue and 2026 guidance raised with development milestones TG Therapeutics announced strong 2025 preliminary results and optimistic 2026 guidance for its lead drug BRIUMVI (ublituximab), a treatment for relapsing multiple sclerosis. The company repo | 2026-01-13 |
| Raises full year 2025 revenue guidance to $600 million TG Therapeutics reported strong Q3 2025 results with BRIUMVI U.S. net revenue of $152.9 million, up 84% year-over-year and 10% from Q2. The company raised its full-year 2025 guidance: global | 2025-11-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for TG Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.